Vanguard Global Advisers
IKT icon

Vanguard Global Advisers’s Inhibikase Therapeutics IKT Stock Holding History

Vanguard Global Advisers’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.2K Hold
36,546
– – ﹤0.01% 2922
2026
Q1 		$61.4K Buy
+36,546
New +$64.9K ﹤0.01% 2930

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Global Advisers's IKT Position: Q2 2026 in Review

Vanguard Global Advisers held its Inhibikase Therapeutics (IKT) position steady in Q2 2026 at 36,546 shares worth $74.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2922.

Vanguard Global Advisers first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Vanguard Global Advisers held 36,546 shares of Inhibikase Therapeutics worth $74.2K as of Q2 2026.
  • Vanguard Global Advisers left its Inhibikase Therapeutics share count unchanged in Q2 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2922 holding.
  • Vanguard Global Advisers first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.